Pyxis Oncology (PYXS) Short-term Investments (2021 - 2026)

Pyxis Oncology (PYXS) has reported Short-term Investments for 5 consecutive years, with $51.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Short-term Investments fell 52.13% year-over-year to $51.4 million; the TTM figure through Dec 2025 stood at $51.4 million (down 52.13% YoY), while the FY2025 annual figure was $51.4 million, down 52.13% from the prior year.
• Short-term Investments declined to $51.4 million in Q4 2025 per PYXS's latest filing, from $67.3 million in the prior quarter.
• Across five years, Short-term Investments topped out at $132.8 million in Q3 2024 and bottomed at $1.5 million in Q4 2021.
• Historically, Short-term Investments has averaged $35.5 million across 5 years, with a median of $1.5 million in 2021.
• Annual changes were most pronounced in 2023 — Short-term Investments jumped 7933.42% — and 2025, when it plunged 52.13%.
• Pyxis Oncology's Short-term Investments stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then surged by 7347.96% to $109.6 million in 2023, then dropped by 1.98% to $107.5 million in 2024, then slumped by 52.13% to $51.4 million in 2025.
• Business Quant data shows PYXS's Short-term Investments at $51.4 million in Q4 2025, $67.3 million in Q3 2025, and $1.5 million in Q2 2025.